PRECIGEN Investors

Press Releases

Press Releases

Upcoming Events

Dec 11, 2021 at 5:30 PM - 7:50 PM EST
An abstract highlighting PRGN-3007 preclinical data (Abstract# 1694) titled, “Preclinical evaluation of PRGN-3007, a non-viral, multigenic, autologous ROR1 UltraCAR-T® cell therapy with novel mechanism of intrinsic PD-1 blockade for treatment of hematological and solid cancers,” will be presented as a poster presentation.
Read More
Dec 13, 2021 at 5:00 PM EST
An abstract for the PRGN-3006 Phase 1 trial (Abstract# 825) titled, "Phase 1/1b Safety Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes," was selected for oral presentation and will be presented by David Sallman, MD, Assistant Member in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute and a lead investigator for the PRGN-3006 clinical trial.
Read More
Media Kit

Precigen maintains a media kit with our corporate logo and our CEO’s headshot and bio that can be used by media for editorial purposes. Should you have any questions or seek assets not included in our media kit, please contact:

press@precigen.com

Download
Media Kit